COPAY ACCUMULATOR PROGRAMS & PHARMA: WHAT’S NEXT?

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

whitePaper | May 22, 2021

One of the key roles of the generic and biosimilar medicines industry is specifically to promote the widest possible access to affordable medicines with high quality, safety, and efficacy for patients globally by introducing competition into the markets. Despite the many hurdles, the generic medicines companies have clearly lived up to the challenges posed by the pandemic as it is an industry that is quick to adapt and agile in manufacturing scale-up. During the outbreak of COVID-19, this industry was providing most of the medicines needed in Intensive Care Units to ventilate critically ill COVID patients. It is also providing most of the quality medicines dispensed around the world, especially for increasingly prevalent chronic diseases and is therefore a strong contributor to health outcomes globally.

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

whitePaper | November 24, 2022

The pharmaceutical industry will face many challenges over the next decade, from industry-wide trends to new operational pressures. The key to meeting these challenges is adopting an agile, scalable and efficient approach to drug discovery and manufacturing.

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.